RESUMEN
Environmental sampling in hospitals is becoming increasingly important because of the rise in nosocomial infections. In order to monitor and track these infections and optimize cleaning and disinfection, we need to be able to locate the fomites with the highest amount of microorganisms, but the optimal method for this is not clear. The aim of this study was to evaluate which of four different dipslides or a standard TSA contact plate were best at recovering human bacteria from the environment. We tested four different dipslides with selective and non-selective agars versus a standard TSA contact plate in order to find the best sampling media. Two hundred sites in a children's medical ward in Copenhagen University hospital were sampled in autumn 2012. There was no difference in total bacteria count between the TSA contact plate and the dipslides. Faecal indicator bacteria recovery was the same for the dipslides and the TSA contact plate. Dipslides may be equally well suited for environmental sampling and hygiene assessment as TSA contact plates. Dipslides have some advantages, such as better sample security, easier sampling in confined spaces and longer shelf life that may speak in favour of choosing these for bacteria environmental sampling in hospitals, depending on the task.
Asunto(s)
Bacterias/aislamiento & purificación , Microbiología Ambiental , Fómites/microbiología , Manejo de Especímenes/métodos , Medios de Cultivo/química , Dinamarca , Hospitales , HumanosRESUMEN
We have investigated the effect of short-term preexposure of growth hormone-releasing hormone (GHRH) on the subsequent response to GHRH in a baby hamster kidney (BHK) cell line expressing the human GHRH receptor and in primary rat pituitary cells. In the BHK cells the receptor was rapidly desensitised in a homologous fashion. Preexposure with agents directly stimulating the cAMP pathway like forskolin and db-cAMP had no effect. In rat pituitary cells we also observed a rapid desensitisation of the GHRH response in an apparently homologous fashion. In both systems the desensitisation was dose-dependent with no change in the potency of the hormone in a subsequent stimulation, only the efficacy was decreased. In the rat pituitary cell, the response measured as growth hormone release was more sensitive to the agonist-induced desensitisation than the cAMP response. No indication of depletion of growth hormone (GH) stores was seen. In rat pituitary cells, contrary to observations in BHK cells, preexposure with both forskolin and db-cAMP desensitised a subsequent growth hormone-releasing hormone stimulation, indicating a heterologous desensitisation. Phorbol-12-myristate 13-acetate (PMA), on the other hand, had no effect. In the baby hamster kidney cells it was demonstrated that the GHRH receptor surface expression decreased following preexposure with GHRH. This phenomenon was observed only in whole cells suggesting a rapid internalisation process. Together, these data indicate that after short-term GHRH preexposure, both in a human and rat system, the following GHRH response is desensitised. In BHK cells this desensitisation is strictly homologous. In rat pituitary cells, on the other hand, the desensitisation is a mixed homologous/ heterologous type.
Asunto(s)
Regulación hacia Abajo , Riñón/efectos de los fármacos , Hipófisis/efectos de los fármacos , Receptores de Neuropéptido/metabolismo , Receptores de Hormona Reguladora de Hormona Hipofisaria/metabolismo , Sermorelina/farmacología , Adenilil Ciclasas/metabolismo , Animales , Animales Recién Nacidos , Bucladesina/farmacología , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Colforsina/farmacología , Cricetinae , Relación Dosis-Respuesta a Droga , Humanos , Riñón/citología , Riñón/enzimología , Masculino , Hipófisis/citología , Hipófisis/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Neuropéptido/agonistas , Receptores de Hormona Reguladora de Hormona Hipofisaria/agonistas , Acetato de Tetradecanoilforbol/farmacología , TransfecciónRESUMEN
The highly potent vanilloid receptor (VR) agonist resiniferatoxin has been radiolabeled with 125I, and the pharmacology to the cloned rodent VR, VR1, and the endogenous VR in rat spinal cord membranes has been characterized. [125I]RTX binding to human embryonic kidney 293 cells expressing VR1 was reversible and with high affinity (Kd = 4.3 nM) in an apparent monophasic manner. In rat spinal cord membranes, [125I]RTX bound with a similar high affinity (Kd = 4.2 nM) to a limited number of binding sites (Bmax = 51 +/- 8 fmol/mg of protein). The pharmacology of recombinant rodent VR1 and the endogenous rat VR1 was indistinguishable when measuring displacement of [125I]RTX binding (i.e., the following rank order of affinity was observed: RTX > I-RTX > olvanil > capsaicin > capsazepine). Capsaicin and RTX induced large nondesensitizing currents in Xenopus laevis oocytes expressing VR1 (EC50 values were 1300 nM and 0.2 nM, respectively), whereas I-RTX induced no current per se at concentrations up to 10 microM. However, I-RTX completely blocked capsaicin-induced currents (IC50 = 3.9 nM). In vivo, I-RTX effectively blocked the pain responses elicited by capsaicin (ED50 = 16 ng/mouse, intrathecally). The present study showed that I-RTX is at least 40-fold more potent than the previously known VR antagonist, capsazepine. Thus, I-RTX as well as its radiolabeled form, should be highly useful for further exploring the physiological roles of VRs in the brain and periphery.
Asunto(s)
Diterpenos/farmacología , Receptores de Droga/antagonistas & inhibidores , Analgésicos/farmacología , Animales , Unión Competitiva , Capsaicina/farmacología , Células Cultivadas , Diterpenos/uso terapéutico , Interacciones Farmacológicas , Humanos , Radioisótopos de Yodo , Ratones , Oocitos , Dolor/tratamiento farmacológico , Dimensión del Dolor/efectos de los fármacos , Ensayo de Unión Radioligante , Receptores de Droga/metabolismo , Canales Catiónicos TRPV , Transfección , Xenopus laevisRESUMEN
To evaluate the postulated role of extrastriatal D1 receptors in human cognition and psychopathology requires an accurate and reliable method for quantification of these receptors in the living human brain. [11C]NNC 112 is a promising novel radiotracer for positron emission tomography imaging of the D1 receptor. The goal of this study was to develop and evaluate methods to derive D1 receptor parameters in striatal and extrastriatal regions of the human brain with [11C]NNC 112. Six healthy volunteers were studied twice. Two methods of analysis (kinetic and graphical) were applied to 12 regions (neocortical, limbic, and subcortical regions) to derive four outcome measures: total distribution volume, distribution volume ratio, binding potential (BP), and specific-to-nonspecific equilibrium partition coefficient (k3/k4). Both kinetic and graphic analyses provided BP and k3/k4 values in good agreement with the known distribution of D1 receptors (striatum > limbic regions = neocortical regions > thalamus). The identifiability of outcome measures derived by kinetic analysis was excellent. Time-stability analysis indicated that 90 minutes of data collection generated stable outcome measures. Derivation of BP and k3/k4 by kinetic analysis was highly reliable, with intraclass correlation coefficients (ICCs) of 0.90+/-0.06 (mean +/- SD of 12 regions) and 0.84+/-0.11, respectively. The reliability of these parameters derived by graphical analysis was lower, with ICCs of 0.72+/-0.17 and 0.58+/-0.21, respectively. Noise analysis revealed a noise-dependent bias in the graphical but not the kinetic analysis. In conclusion, kinetic analysis of [11C]NNC 112 uptake provides an appropriate method with which to derive D1 receptor parameters in regions with both high (striatal) and low (extrastriatal) D1 receptor density.
Asunto(s)
Benzazepinas , Benzofuranos , Cuerpo Estriado/metabolismo , Receptores de Dopamina D1/metabolismo , Tomografía Computarizada de Emisión/normas , Adulto , Artefactos , Benzazepinas/sangre , Benzazepinas/farmacocinética , Benzofuranos/sangre , Benzofuranos/farmacocinética , Radioisótopos de Carbono , Cerebelo/química , Cerebelo/diagnóstico por imagen , Cerebelo/metabolismo , Cuerpo Estriado/química , Cuerpo Estriado/diagnóstico por imagen , Antagonistas de Dopamina/farmacocinética , Femenino , Humanos , Cinética , Masculino , Persona de Mediana Edad , Neocórtex/química , Neocórtex/diagnóstico por imagen , Neocórtex/metabolismo , Ensayo de Unión Radioligante/métodos , Ensayo de Unión Radioligante/normas , Reproducibilidad de los Resultados , Tomografía Computarizada de Emisión/métodosRESUMEN
The hexapeptide ac-RYYRWK-NH2 has been described as a potent partial agonist at the nociceptin (NC)/orphanin FQ receptor which has no affinity for mu-, kappa- or delta-opioid receptors. However, it is not clear whether ac-RYYRWK-NH2 is truly selective for the NC receptor, and ac-RYYRWK-NH2 has therefore been radiolabelled and characterised in receptor-binding experiments. Saturation experiments with [3H]ac-RYYRWK-NH2 binding to rat cortical membranes revealed a single high affinity site for [3H]ac-RYYRWK-NH2 (Kd=0.071 +/- 0.018 nM; Bmax=22+/-2 fmol/mg protein). Uncoupling of the G-proteins resulted in a significant 45% increase in Kd and no change in Bmax. [3H]ac-RYYRWK-NH2 binding to rat cortical membranes or to membranes from baby hamster kidney cells expressing human orphan opioid receptor-like (ORL1) was displaced by NC and ac-RYYRWK-NH2 to the same extent. The following rank order of potency was observed: ac-RYYRWK-NH2 > [Tyr14]NC-OH = NC-OH = NC-NH2 > NC, H-(1-13)-NH2 > NC(1-12)-NH2 >> NC(1-11)-NH2 and, thus, displayed a typical NC receptor pharmacology. Novel cyclic analogues of ac-RYYRWK-NH2 were prepared but these structures were much less active when compared to ac-RYYRWK-NH2. In vitro receptor autoradiography with [3H]ac-RYYRWK-NH2 to rat brain sections revealed high levels of binding in the cerebral cortex, amygdala, hypothalamus and superior colliculus, but low levels in the cerebellum and striatum. Overall, the regional distribution was very similar to that of [3H]NC. Ac-RYYRWK-NH2 seems indeed to be selective for the NC receptor and [3H]ac-RYYRWK-NH2 is a novel radioligand which may be useful for further exploring the pharmacology and receptor-ligand interaction of the NC receptor.
Asunto(s)
Oligopéptidos/metabolismo , Receptores Opioides/metabolismo , Amígdala del Cerebelo/metabolismo , Animales , Autorradiografía , Sitios de Unión , Unión Competitiva , Membrana Celular/metabolismo , Corteza Cerebral/metabolismo , Cricetinae , Femenino , Humanos , Hipotálamo/metabolismo , Cinética , Oligopéptidos/farmacología , Péptidos Opioides/metabolismo , Péptidos Opioides/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores Opioides/agonistas , Especificidad por Sustrato , Tritio , Receptor de NociceptinaRESUMEN
NNC 756 ((+)-8-chloro-5-(2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine) is a new high affinity dopamine (DA) D1 receptor antagonist. Labeled with C-11, it has been used as a PET radiotracer to visualize D1 receptors both in striatal and extrastriatal areas, such as the prefrontal cortex. The goal of this study was to evaluate several methods for derivation of D1 receptor binding potential (BP) with [11C]NNC 756 in baboons, and to use these methods to assess the vulnerability of [11C]NNC 756 binding to competition by endogenous DA. A three-compartment model provided a good fit to PET data acquired following a single bolus injection. BP values obtained with this analysis were in good agreement with values derived from in vitro studies. BP values measured following injection of the potent DA releaser amphetamine (1 mg/kg, n=2) were similar to values measured under control conditions. Kinetic parameters derived from single bolus experiments were used to design a bolus plus continuous infusion administration protocol aimed at achieving a state of sustained binding equilibrium. Injection of amphetamine during sustained equilibrium did not affect [11C]NNC 756 binding. Similar results were observed with another D1 radiotracer, [11C]SCH 23390. Doses of amphetamine used in this study are known to reduce by 20-40% the binding potential of several D2 receptors radiotracers. Therefore, the absence of displacement of [11C]NNC 756 by an endogenous DA surge may indicate important differences between D1 and D2 receptors in vivo, such as differences in proportion of high affinity states not occupied by DA at baseline. These findings may also imply that a simple binding competition model is inadequate to account for the effects of manipulation of endogenous DA levels on the in vivo binding of radiolabeled antagonists.
Asunto(s)
Benzazepinas/farmacocinética , Benzofuranos/farmacocinética , Química Encefálica/fisiología , Antagonistas de Dopamina/farmacocinética , Dopamina/metabolismo , Receptores de Dopamina D1/metabolismo , Anfetamina/farmacología , Animales , Benzazepinas/sangre , Benzazepinas/farmacología , Benzofuranos/sangre , Unión Competitiva/efectos de los fármacos , Unión Competitiva/fisiología , Química Encefálica/efectos de los fármacos , Radioisótopos de Carbono , Corteza Cerebral/química , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/metabolismo , Cuerpo Estriado/química , Cuerpo Estriado/diagnóstico por imagen , Cuerpo Estriado/metabolismo , Dopaminérgicos/farmacología , Antagonistas de Dopamina/sangre , Antagonistas de Dopamina/farmacología , Femenino , Imagen por Resonancia Magnética , Masculino , Papio , Racloprida , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/análisis , Salicilamidas/farmacología , Tálamo/química , Tálamo/diagnóstico por imagen , Tálamo/metabolismo , Tomografía Computarizada de EmisiónRESUMEN
The hypothalamic satiety peptide CART (cocaine and amphetamine regulated transcript) is expressed at high levels in anorectic rat glucagonomas but not in hypoglycemic insulinomas. However, a non-anorectic metastasis derived from the glucagonoma retained high CART expression levels and produced circulating CART levels comparable to that of the anorectic tumors. Moreover, distinct glucagonoma lines derived by stable HES-1 transfection of the insulinoma caused severe anorexia but retained low circulating levels of CART comparable to that of insulinoma bearing or control rats. Islet tumor associated anorexia and circulating CART levels are thus not correlated, and in line with this peripheral administration of CART (5-50 mg/kg) produced no effect on feeding behavior. In the rat two alternatively spliced forms of CART mRNA exist and quantitative PCR revealed expression of both forms in the hypothalamus, in the different islet tumors, and in the islets of Langerhans. Immunocytochemistry as well as in situ hybridization localized CART expression to the somatostatin producing islet D cell. A potential endocrine/paracrine role of islet CART remains to be clarified.
Asunto(s)
Adenoma de Células de los Islotes Pancreáticos/sangre , Adenoma de Células de los Islotes Pancreáticos/genética , Anorexia/sangre , Anorexia/genética , Islotes Pancreáticos/metabolismo , Proteínas del Tejido Nervioso/sangre , Proteínas del Tejido Nervioso/genética , Neoplasias Pancreáticas/sangre , Neoplasias Pancreáticas/genética , Animales , Secuencia de Bases , Sondas de ADN/genética , Ingestión de Alimentos/efectos de los fármacos , Femenino , Expresión Génica , Glucagonoma/sangre , Glucagonoma/genética , Inmunohistoquímica , Hibridación in Situ , Insulinoma/sangre , Insulinoma/genética , Proteínas del Tejido Nervioso/farmacología , ARN Mensajero/genética , ARN Neoplásico/genética , Ratas , Células Secretoras de Somatostatina/metabolismoRESUMEN
UNLABELLED: The aim of this work was to explore the potential of a selective D1-dopamine receptor antagonist as a new radioligand for PET examination of striatal and neocortical D1-dopamine receptors. METHODS: The active (+)- and inactive (-)-enantiomers of [11C]NNC 112 were radiolabeled using the N-methylation approach and were examined by PET in cynomolgus monkeys and healthy men. Metabolite levels in plasma were measured by gradient high-performance liquid chromatography (HPLC). RESULTS: N-methylation of the corresponding desmethyl precursors with [11C]methyl triflate gave high total radiochemical yield (50%-60%) and specific radioactivity (110 GBq/micromol). (+)-[11C]NNC 112 binding in cynomolgus monkeys was 5.77+/-0.31 and 2.36+/-0.14 times higher in the striatum and neocortex, respectively, than in the cerebellum at a transient equilibrium that appeared 40-50 min after injection. The binding of (+)-[11C]NNC 112 is stereoselective, because the brain distribution of the inactive (-)-enantiomer was on an equally low level for all brain regions. Displacement and pretreatment experiments using unlabeled SCH 23390 and ketanserin confirms that (+)-[11C]NNC 112 binds specifically and reversibly to D1-dopamine receptors. The radioactivity ratios of the striatum, frontal cortex and nucleus accumbens to the cerebellum were 3.8-4.0, 1.7-2.0 and 2.8-3.1, respectively, at a transient equilibrium that appeared 40-50 min after injection in four healthy human subjects. Linear graphical analysis gave distribution volume ratios of 3.9 and 1.5 in the putamen and frontal cortex, respectively. The fraction of the total radioactivity in human plasma representing unchanged (+)-[11C]NNC 112 was 85% at 5 min and 25% at 75 min after injection. CONCLUSION: (+)-[11C]NNC 112 should be a useful PET radioligand for quantitative examination of not only striatal but neocortical D1-dopamine receptors in man.
Asunto(s)
Benzazepinas/farmacocinética , Benzofuranos/farmacocinética , Radioisótopos de Carbono/farmacocinética , Cuerpo Estriado/metabolismo , Antagonistas de Dopamina/farmacocinética , Neocórtex/metabolismo , Receptores de Dopamina D1/metabolismo , Adulto , Animales , Unión Competitiva , Cuerpo Estriado/diagnóstico por imagen , Humanos , Cinética , Macaca fascicularis , Masculino , Neocórtex/diagnóstico por imagen , Ensayo de Unión Radioligante , Receptores de Dopamina D1/análisis , Sensibilidad y Especificidad , Estereoisomerismo , Tomografía Computarizada de EmisiónRESUMEN
NNC 22-0215 has been found to be a metabolically stable dopamine D1 antagonist with high affinity and selectivity for D1 receptors in vitro. We prepared [11C]NNC 22-0215 with a specific radioactivity of about 50 GBq/micromol at time of administration. In PET experiments with [11C]NNC 22-0215 there was a rapid uptake of radioactivity in the cynomolgus monkey brain (1.8% of total radioactivity injected). Radioactivity accumulated most markedly in the striatum and the neocortex. The striatum to cerebellum ratio was about 4, with specific binding that remained at a plateau level from 50 min to 100 min after injection. Binding in the striatum and neocortex was markedly displaced by SCH 23390, whereas binding in the cerebellum was not reduced. Metabolite studies showed that about 80% of the radioactivity in the monkey plasma represented unchanged radioligand 30 min after injection. The rate of metabolism in monkey plasma in vivo was also determined for a series of structurally related 11C-labelled benzazepines, previously used as dopamine D1 receptor ligands for PET. Results indicate a significantly slower rate of metabolism for [11C]NNC 22-0215 than for any of the previously labelled benzazepines. Thus [11C]NNC 22-0215 has potential for imaging of selective binding to the dopamine D1 receptors in the human brain with high count rates at time of equilibrium.
Asunto(s)
Benzazepinas/síntesis química , Benzofuranos/síntesis química , Radiofármacos/síntesis química , Receptores de Dopamina D1/metabolismo , Animales , Benzazepinas/farmacocinética , Benzazepinas/farmacología , Benzofuranos/farmacocinética , Benzofuranos/farmacología , Unión Competitiva , Humanos , Marcaje Isotópico , Ligandos , Macaca fascicularis , Radiofármacos/farmacocinética , Radiofármacos/farmacología , Receptores de Dopamina D1/efectos de los fármacos , Tomografía Computarizada de EmisiónRESUMEN
Porcine pancreatic secretory phospholipase A2 (ppsPLA2) has been shown to modulate agonist and antagonist binding to alpha-amino-3-hydroxy-5-methylisoxazolepropionate (AMPA) receptors and to effect neurotransmission in the central nervous system (CNS). To further elucidate the mechanism of action of ppsPLA2 in the CNS, the binding profile of 125I-labelled ppsPLA2 to rat whole-brain membranes was assessed. Two classes of calcium-dependent binding sites were detected using unlabelled ppsPLA2 as a displacer with IC50 values of 3 and 217 nM. Similar values were obtained for [125I]ppsPLA2 binding to membranes prepared from isolated cortical and hippocampal rat brain regions. [125I]ppsPLA2 binding displayed bell-shaped concentration-dependence curves to Ca2+, Zn2 + and pH. Binding was not inhibited by AMPA, the false substrate, oleoyloxyethyl phosphocholine (OOPC), or by BSA-galactose or wheat germ agglutinin. [125I]ppsPLA2 binding was reduced by treatment of the rat brain membranes with mercaptoethanol and proteinase K treatment or by their pre-incubation at 95 degrees C. These results show a different binding profile to the previously characterised snake venom sPLA2 N-type receptors and suggest the existence of novel class of sPLA2 N-type binding sites.
Asunto(s)
Corteza Cerebral/metabolismo , Hipocampo/metabolismo , Páncreas/enzimología , Fosfolipasas A/metabolismo , Sinaptosomas/metabolismo , Animales , Sitios de Unión , Unión Competitiva , Calcio/farmacología , Membrana Celular/metabolismo , Femenino , Concentración de Iones de Hidrógeno , Membranas Intracelulares/metabolismo , Radioisótopos de Yodo , Cinética , Fosfolipasas A2 , Ratas , Ratas Wistar , Porcinos , Zinc/farmacologíaRESUMEN
NNC 13-8241 has recently been labelled with iodine-123 and developed as a metabolically stable benzodiazepine receptor ligand for single-photon emission computed tomography (SPECT) in monkeys and man. NNC 13-8199 is a bromo-analogue of NNC 13-8241. This partial agonist binds selectively and with subnanomolar affinity to the benzodiazepine receptors. We prepared 76Br labelled NNC 13-8199 from the trimethyltin precursor by the chloramine-T method. Carbon-11 labelled NNC 13-8199 was synthesised by N-alkylation of the nitrogen of the amide group with [11C]methyl iodide. Positron emission tomography (PET) examination with the two radioligands in monkeys demonstrated a high uptake of radioactivity in the occipital, temporal and frontal cortex. In the study with [76Br]NNC 13-8199, the monkey brain uptake continued to increase until the time of displacement with flumazenil at 215 min after injection. For both radioligands the radioactivity in the cortical brain regions was markedly reduced after displacement with flumazenil. More than 98% of the radioactivity in monkey plasma represented unchanged radioligand 40 min after injection. The low degree of metabolism indicates that NNC 13-8199 is metabolically much more stable than hitherto developed PET radioligands for imaging of benzodiazepine receptors in the primate brain. [76Br]NNC 13-8199 has potential as a radioligand in human PET studies using models where a slow metabolism is an advantage.
Asunto(s)
Benzodiazepinas , Encéfalo/diagnóstico por imagen , Agonistas de Receptores de GABA-A , Oxadiazoles , Tomografía Computarizada de Emisión , Animales , Encéfalo/metabolismo , Radioisótopos de Bromo , Radioisótopos de Carbono , Flumazenil , Humanos , Macaca fascicularis , Masculino , Papio , Receptores de GABA-A/metabolismoRESUMEN
1. The purpose of the present study was to characterize the binding of the histamine H3 receptor antagonist, [3H]-thioperamide, to rat cerebral cortical membranes. 2. The binding of [3H]-thioperamide to rat cerebral cortical membranes reached equilibrium after incubation with [3H]-thioperamide after 8-10 h at 4 degrees C. Equilibrium was maintained for up to 18 h of incubation. Addition of 1 microM (R)-alpha-methylhistamine rapidly dissociated [3H]-thioperamide from its binding sites. From these kinetic experiments a dissociation constant of 0.3 nM was obtained for [3H]-thioperamide. 3. Saturation experiments with [3H]-thioperamide using 1 microM (R)-alpha-methylhistamine to define nonspecific binding were best analysed according to a single site model. A dissociation constant (KD) of 0.80 +/- 0.06 nM (n = 3) and a maximal number of binding sites (Bmax) of 73 +/- 20 fmol mg-1 protein (n = 3) were obtained for the binding of [3H]-thioperamide to rat cerebral cortical membranes. 4. Saturation experiments with [3H]-thioperamide using 0.3 microM iodophenpropit to define nonspecific binding were best analysed according to a two site model. For the high affinity [3H]-thioperamide site a KD value of 1.1 +/- 0.3 nM (n = 3) and Bmax value of 162 +/- 108 fmol mg-1 protein (n = 3) were obtained whereas KD and Bmax values for the low affinity site were 96 +/- 19 nM and 4346 +/- 3092 fmol mg-1 protein (n = 3), respectively. 5. Using 5 nM [3H]-thioperamide, the binding was hardly displaced by H3 agonists within concentration-ranges expected to bind to the histamine H3 receptor. Under these conditions, [3H]-thioperamide binding was fully displaced by various H3-antagonists, yet most H3 antagonists showed Ki values different from those expected for the histamine H3 receptor. 6. Using 0.3 nM [3H]-thioperamide, 50-60% of the total binding was potently displaced by the H3 agonists histamine, (R)-alpha-methylhistamine, (S)-alpha-methylhistamine, imetit and immepip. Displacement of the binding of 0.3 nM [3H]-thioperamide binding exhibited clear stereoselectivity for the R and S isomers of alpha-methylhistamine. 7. Binding of 0.3 nM [3H]-thioperamide was completely displaced by several H3 antagonists (thioperamide, iodophenpropit, iodoproxyfan, and burimamide) and biphasic displacement curves were obtained; the Ki values for the high affinity site corresponded well with the expected values for the H3 receptor. Antagonists fully displaced the binding of 5 nM [3H]-thioperamide with affinities comparable to the low affinity site found with 0.3 nM [3H]-thioperamide. 8. Ondansetron and haloperidol did not displace binding of 5 nM [3H]-thioperamide at concentrations at which the former are known to bind to 5-HT3 or sigma receptors, respectively. On the other hand, nonselective cytochrome P450 inhibitors displaced the binding of 5 nM [3H]-thioperamide from both rat cerebral cortical membranes and rat liver microsomes. 9. It is concluded that the histamine H3 antagonist, [3H]-thioperamide, can be used as a radioligand to study the histamine H3 receptor in rat brain, provided that subnanomolar concentrations are used in displacement studies. Moreover, the specific binding should be defined with an H3 agonist, since most H3 antagonists share with [3H]-thioperamide a low affinity, high density, non-H3 receptor binding site(s) in rat brain. The latter is probably due to binding to cytochrome P450 isoenzymes.
Asunto(s)
Corteza Cerebral/efectos de los fármacos , Antagonistas de los Receptores Histamínicos/farmacología , Piperidinas/farmacología , Receptores Histamínicos/efectos de los fármacos , Animales , Relación Dosis-Respuesta a Droga , Imidazoles/farmacología , Isotiuronio/análogos & derivados , Isotiuronio/farmacología , Masculino , Ensayo de Unión Radioligante , Ratas , Ratas WistarRESUMEN
NNC 22-0010 is a new dopamine antagonist with a high affinity and selectivity for D1 receptors in vitro. NNC 22-0010 has both an N-methyl group and a bromine, which allows radiolabelling with either 11C or 76Br. We labelled [11C]NNC 22-0010 by N-methylation of the free base of the secondary amine with [11C]methyl iodide in a total radiochemical yield of 40%. The total synthesis time was 30 min. The specific radioactivity at time of injection of the radioligand was 48 to 55 GBq/mumol. The [76Br]NNC 22-0010 was synthesized from the iodine precursor by an exchange reaction with 76Br using a Cu(+)-assisted nucleophilic substitution reaction. The radiochemical yield was 60% after purification. Specific radioactivity at time of injection of the radioligand was 6 to 20 GBq/mumol. In PET experiments with [11C]NNC 22-0010 and [76Br]NNC 22-0010 there was a rapid uptake of radioactivity in the monkey brain. The striatum-to-cerebellum ratio was 2-2.5 after 1 h. Binding in the striatum was displaced by SCH 23390, whereas binding in the cerebellum was not reduced. Metabolite studies showed that 1 h after injection about 20% of the radioactivity in plasma represented unchanged radioligand. This value was on the same level for at least 6 h. The results indicate that radiolabelled NNC 22-0010 has potential for imaging dopamine D1 receptors selectively in the human brain.
Asunto(s)
Benzazepinas/síntesis química , Benzazepinas/farmacología , Benzofuranos/síntesis química , Benzofuranos/farmacología , Radioisótopos de Bromo , Radioisótopos de Carbono , Antagonistas de Dopamina/síntesis química , Antagonistas de Dopamina/farmacología , Receptores de Dopamina D1/antagonistas & inhibidores , Receptores de Dopamina D1/metabolismo , Animales , Benzazepinas/metabolismo , Benzofuranos/metabolismo , Encéfalo/diagnóstico por imagen , Encéfalo/ultraestructura , Antagonistas de Dopamina/metabolismo , Marcaje Isotópico , Macaca fascicularis , Masculino , Papio , Ensayo de Unión Radioligante , Especificidad por Sustrato , Tomografía Computarizada de EmisiónRESUMEN
Xanomeline, a substituted TZTP, is a new M1 selective muscarinic agonist in clinical trials for Alzheimer's disease. The brain uptake of [11C]xanomeline and the analog [11C]butylthio-TZTP was examined by positron emission tomography (PET). Radioactivity accumulated most markedly in the neocortex and the striatum. Pharmacological characterization in vitro and in cynomolgus monkeys in vivo by PET indicated specific [11C]butylthio-TZTP binding to muscarinic receptors and to sigma-1 recognition sites. More than 5% of the radioactivity was in the human brain 5 min after i.v. injection of [11C]xamomeline or [11C]butylthio-TZTP. This high brain uptake may be clinically advantageous in the sense that substituted TZTP may induce central muscarinic agonist effects at a dose level for which there is a low risk of peripheral side-effects.
Asunto(s)
Encéfalo/metabolismo , Agonistas Muscarínicos/farmacocinética , Piridinas/farmacocinética , Tiadiazoles/farmacocinética , Adulto , Animales , Encéfalo/diagnóstico por imagen , Humanos , Macaca fascicularis , Masculino , Receptores Muscarínicos/metabolismo , Receptores sigma/metabolismo , Especificidad de la Especie , Tomografía Computarizada de Emisión , Tomografía Computarizada por Rayos XRESUMEN
The iodine-123 labelled ligand 3-(5-cyclopropyl-1,2, 4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1, 5-a][1,4]-benzodiazepine ([123I]NNC 13-8241) was evaluated as a probe for in vivo imaging of benzodiazepine receptor sites in the human brain. Four healthy volunteers were imaged with a high-resolution single-photon emission tomography (SPET) scanner. The metabolism of [123I]NNC 13-8241 in plasma was slow. The total brain uptake was about 1.5-fold higher than that of [123I]iomazenil. The specific binding in the cortical areas was high and less intense in the thalamus. The most intense uptake was seen in the occipital cortex. The peak cortical uptake of [123I]NNC 13-8241 was observed 6-10 h after the injection of tracer. The radiation burden to the patient was moderate, being 2.5 middle dot10(-2 )mSv/MBq (effective dose equivalent). A slow metabolism together with favourable kinetics indicates that [123I]NNC 13-8241 is a specific and promising SPET ligand for imaging benzodiazepine receptor sites in the living human brain.
Asunto(s)
Benzodiazepinas , Encéfalo/diagnóstico por imagen , Radioisótopos de Yodo , Receptores de GABA-A/análisis , Tomografía Computarizada de Emisión de Fotón Único , Adulto , Humanos , Masculino , Dosis de Radiación , Distribución TisularRESUMEN
[125I]- and [123I]NNC 13-8241 were prepared from the trimethyltin precursor and radioactive iodide using the chloramine-T method. The total radiochemical yields of [125I]- and [123I]NNC 13-8241 were 60-70% and 40-50% respectively, with radiochemical purity higher than 98%. In binding studies with [125I]NNC 13-8241 in rats in vitro and in vivo a high uptake of radioactivity was demonstrated in brain regions known to have a high density of benzodiazepine (BZ) receptors such as the occipital and frontal cortex. SPECT examination with [123I]NNC 13-8241 in a Cynomolgus monkey demonstrated a high uptake of radioactivity in the occipital and frontal cortex. After displacement with flumazenil radioactivity in these brain regions was reduced to the level of a central region including the pons. Four hours after injection about 80% of the radioactivity in monkey plasma represented unchanged radioligand. This low degree of metabolism indicates that NNC 13-8241 is metabolically more stable than the radioligands hitherto developed for imaging of BZ-receptors in the primate brain.
Asunto(s)
Benzodiazepinas/metabolismo , Radioisótopos de Yodo , Receptores de GABA-A/análisis , Tomografía Computarizada de Emisión , Animales , Benzodiazepinas/farmacocinética , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/metabolismo , Cromatografía Líquida de Alta Presión , Radioisótopos de Yodo/farmacocinética , Marcaje Isotópico/métodos , Macaca fascicularis , Masculino , Ensayo de Unión Radioligante/métodos , Ratas , Ratas Wistar , Receptores de GABA-A/metabolismo , Distribución TisularRESUMEN
A steady state method for neuroreceptor quantification in vivo in small laboratory animals is described, using [123I]iomazenil as tracer for the benzodiazepine receptor. The method was used for determination of the receptor equilibrium constant for a non-radioactive ligand, flumazenil, in rats and involved measurement of the nonspecific binding of [123I]iomazenil. Thirty-five animals were intravenously infused for 2 h with [123I]iomazenil and flumazenil in different proportions to obtain occupancies of the benzodiazepine receptor from close to 0 to about 99%. The nonspecific binding of iomazenil in brain tissue was calculated by an iterative procedure from the data for the highly blocked animals, and it was found to be 1.04 ml per ml plasma (n = 6). The mean cortical Kd of flumazenil was 21 +/- 11 nM (n = 19). The method is discussed with special reference to the problems of ascertaining steady state and nonspecific binding.
Asunto(s)
Flumazenil/análogos & derivados , Neuronas/efectos de los fármacos , Receptores de GABA-A/efectos de los fármacos , Animales , Sangre/metabolismo , Encéfalo/metabolismo , Flumazenil/sangre , Flumazenil/farmacología , Masculino , Matemática , Ratas , Ratas WistarRESUMEN
The tritiated dopamine reuptake inhibitor [3H]NNC 12-0781 ([1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2,3-[3H] - propyl)-piperazine) was radiolabelled in one step starting from 1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2-propenyl)- piperazine, using tritium gas and PdO as catalyst. The radiochemical purity of [3H]NNC 12-0781 was higher than 99% after HPLC purification with a specific radioactivity of 21 Ci/mmol. [3H]NNC 12-0781 bound specifically to rat striatum in vitro at +4 degrees C with a Kd of 1.76 nM and Bmax of 587 fmol/mg tissue. The nonspecific binding was about 10% at Kd. At +37 degrees C no acceptable binding was observed. The association of [3H]NNC 12-0781 thus has the characteristics of a radioligand for the dopamine transporter in vitro at +4 degrees C.
Asunto(s)
Encéfalo/metabolismo , Inhibidores de Captación de Dopamina/metabolismo , Glicoproteínas de Membrana , Proteínas de Transporte de Membrana , Proteínas del Tejido Nervioso , Piperazinas/síntesis química , Piperazinas/metabolismo , Animales , Proteínas Portadoras/metabolismo , Membrana Celular/metabolismo , Cromatografía Líquida de Alta Presión , Cuerpo Estriado/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Inhibidores de Captación de Dopamina/síntesis química , Marcaje Isotópico/métodos , Cinética , Masculino , Piperazinas/farmacocinética , Ensayo de Unión Radioligante/métodos , Ratas , Ratas Wistar , TritioRESUMEN
The preparation of no-carrier-added 18F labelled NNC 12-0817 (1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-[4-oxo-4-(2- thienyl)butyl]piperazine) and NNC 12-0818 (1-(2[bis(4- fluorophenyl)methoxy]ethyl)-4-]4-hydroxy-4-(2-thienyl)butyl]piperazine) is described. NNC 12-0818 is the designation of the racemic mixture of two enantiomers. Fluorine-18 is introduced into 4-[18F]fluoro-4'-fluorobenzophenone from the corresponding triflate salt by a nucleophilic aromatic substitution reaction. A no-carrier-added synthesis was performed in 6 steps starting from N,N-dimethylaniline and 4-fluorobenzoyl chloride giving [18F]NNC 12-0817 and [18F]NNC 12-0818 in good yields and a radiochemical purity after HPLC-purification higher than 99%.